Sastasundar Ventures Limited (SASTASUNDR) AI Stock Analysis

• Market Cap: ₹8.84B
• Dividend Yield: N/A
• Average Volume (3M): 4.89K
• Price to Earnings (P/E): 207.7
• Beta (1Y): 0.86
• Revenue Growth: -3.97%
• EPS Growth: 96.73%
• Country: IN
• Employees: 941
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.35
• Shares Outstanding: 31,810,500
• 10 Day Avg. Volume: 1,551
• 30 Day Avg. Volume: 4,895
• PEG Ratio: <0.01
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 0.74
• P/FCF Ratio: -29.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ₹284.00 ▼(-8.93% Downside)
• Action: Reiterated Date: 09/11/25
• Date: Action: Reiterated 09/11/25

The overall stock score of 47 reflects significant financial challenges, including declining revenues and persistent losses. Technical analysis shows neutral to bearish momentum, while valuation metrics are unattractive due to negative earnings. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Low leverage / strong equity base

A high equity ratio and low debt reduce financial risk and give the company a longer runway to invest or restructure without immediate refinancing pressure. This durable balance-sheet strength supports strategic initiatives and cushions cyclical shocks.

Prior revenue growth momentum

Historical revenue growth demonstrates the company has market reach and demand traction in its segments. That underlying ability to grow top line can be leveraged via existing distribution channels and digital offerings to rebuild scale over the medium term.

Consumer-facing healthcare platform and fulfillment capabilities

Owning both digital customer touchpoints and fulfillment/distribution creates structural advantages: recurring customer relationships, potential cross-sell, and differentiated delivery economics versus pure-play competitors, supporting sustainable revenue streams.

Negative Factors

Declining revenues

A material year-over-year revenue decline weakens scale economics and makes fixed-cost absorption harder, pressuring margins and investment capacity. Sustained top-line shrinkage undermines long-term profitability and market positioning if not reversed.

Negative operating cash flow

Persistent negative operating cash flow indicates the core business isn't generating sufficient cash to fund operations and capex. Over months, this raises reliance on external financing, increases liquidity risk, and constrains strategic flexibility.

Persistent losses and negative return on equity

Recurring losses producing negative ROE show the company is not earning a return on capital. Over time this erodes shareholder value, limits retained-earnings reinvestment, and can make it harder to attract growth capital or execute long-term plans.

Sastasundar Ventures Limited Business Overview & Revenue Model

Company Description

Sastasundar Ventures Limited operates a digital network of healthcare in India. It finances loans, and invests in shares and securities, as well as provides financial consultancy, professional fees, wealth management, financial planning, distribution, and related services. The company also operates sastasundar.com and retailershakti.com portal for pathology and healthcare products marketing activities, as well as provides diagnostic services, such as pathological/radiological investigations. In addition, it distributes medicines and wellness products; and provides customized heath supplements and diet counselling, as well as health information services. The company was formerly known as Microsec Financial Services Limited and changed its name to Sastasundar Ventures Limited in November 2016. Sastasundar Ventures Limited was incorporated in 1989 and is based in Kolkata, India.

How the Company Makes Money

Sastasundar Ventures Limited generates revenue through its e-commerce platform, which facilitates the sale of pharmaceutical and healthcare products directly to consumers. The company makes money by purchasing products from manufacturers or authorized distributors at wholesale prices and selling them at a retail margin. Additionally, Sastasundar may earn revenue from partnerships with healthcare providers, pharmacies, and wellness brands looking to reach a broader customer base through its platform. The company's business model focuses on efficiency in supply chain management and cost reduction to offer competitive pricing, thus attracting a larger customer base and driving sales growth.

Sastasundar Ventures Limited Financial Statement Overview

Summary

Sastasundar Ventures Limited faces financial challenges with declining revenues and persistent losses, impacting profitability. The balance sheet shows moderate strength with low debt levels, but operational inefficiencies are evident through negative margins and cash flow issues.

Income Statement

Sastasundar Ventures Limited has shown significant volatility in revenue and profitability. The company experienced a notable decline in revenue from 2024 to 2025, with a decrease from 13.56 billion to 10.89 billion. The net profit margin has been negative, reflecting recurring losses, with net income dropping from a modest profit in 2024 to a significant loss in 2025. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies. A key strength is the prior year revenue growth between 2023 and 2024, but consistent profitability remains a challenge.

Balance Sheet

The company's balance sheet demonstrates moderate strength, with a favorable equity ratio due to a substantial stockholders' equity of 6.70 billion against total assets of 9.74 billion as of 2025. The debt-to-equity ratio is low, signifying minimal leverage, which reduces financial risk. However, the return on equity is negative due to net losses, indicating that the company is not effectively generating returns on its equity base.

Cash Flow

Cash flow analysis indicates challenges, with negative operating cash flow in 2025, pointing to struggles in generating cash from core operations. Free cash flow has also decreased significantly, reflecting negative growth and potential liquidity issues. Positive free cash flow from 2024 did not sustain, which impacts the company's ability to fund operations without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Jun 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.50B	10.90B	13.56B	10.38B	6.30B	5.46B
Gross Profit	790.68M	721.21M	1.20B	711.54M	445.35M	513.28M
EBITDA	-268.79M	-1.87B	-203.51M	-1.13B	11.22B	-109.58M
Net Income	-20.46M	-911.67M	88.83M	-722.11M	6.27B	-104.01M
Balance Sheet
Total Assets	10.08B	9.74B	11.50B	12.06B	12.78B	2.93B
Cash, Cash Equivalents and Short-Term Investments	240.06M	124.44M	3.95B	2.08B	2.12B	124.49M
Total Debt	51.49M	11.88M	38.83M	93.25M	18.53M	152.02M
Total Liabilities	1.32B	1.10B	1.50B	2.12B	1.84B	634.32M
Stockholders Equity	6.81B	6.70B	7.62B	7.53B	8.27B	2.00B
Cash Flow
Free Cash Flow	-326.00M	-276.65M	239.34M	-1.31B	-2.12B	-314.92M
Operating Cash Flow	-271.35M	-173.09M	381.65M	-1.12B	-2.07B	-305.08M
Investing Cash Flow	406.47M	-11.34M	-339.27M	1.33B	2.20B	213.71M
Financing Cash Flow	-19.52M	-4.43M	-23.52M	-18.33M	-114.22M	37.26M

Sastasundar Ventures Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 311.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SASTASUNDR, the sentiment is Negative. The current price of 311.85 is above the 20-day moving average (MA) of 280.33, above the 50-day MA of 292.27, and above the 200-day MA of 295.31, indicating a bearish trend. The MACD of -2.49 indicates Negative momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 24.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SASTASUNDR.

Sastasundar Ventures Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MEDPLUS	62 Neutral	₹95.78B	41.81	―	―	4.94%	94.22%
SASTASUNDR	47 Neutral	₹8.84B	207.74	―	―	-3.97%	96.73%

Sastasundar Ventures Limited Corporate Events

Health X Platform Unit Clears Envision Deal and Merger Framework

Health X Platform Limited has disclosed that the board of its material subsidiary, Sastasundar Healthbuddy Limited, has approved a tripartite agreement with the parent company and Envision India Fund, a Mauritius-based qualified institutional buyer. The agreement is linked to a recently signed share purchase deal under which Envision will acquire Mitsubishi Corporation’s entire shareholding in Sastasundar Healthbuddy Limited.

Under the tripartite structure, Sastasundar Healthbuddy Limited is proposed to be merged into Health X Platform Limited so that Envision’s economic interest in the listed company mirrors its prior stake in the subsidiary, subject to regulatory compliance. If the merger cannot be completed, a share swap will ensure Envision receives equivalent shares in Health X, and Envision will also gain rights to appoint a non-voting board observer and, in certain circumstances, a director to the subsidiary’s board, signaling increased institutional influence and a potential reshaping of the group’s ownership and governance.

Health X Platform Sets Merger Path With Subsidiary as Envision Enters Cap Table

Health X Platform Limited, formerly Sastasundar Ventures Limited, has a key operating arm in Sastasundar Healthbuddy Limited, its material subsidiary engaged in healthcare platform activities. Its shareholder base in the subsidiary includes strategic partner Rohto Pharmaceuticals and institutional investor Envision India Fund, underlining its positioning in technology-enabled healthcare services.

The board of HealthX has approved a Tripartite Agreement with Sastasundar Healthbuddy Limited and Envision India Fund, following Envision’s deal to acquire Mitsubishi Corporation’s entire shareholding in the subsidiary. The agreement envisages a future merger of the subsidiary into HealthX, or alternatively a share swap, to preserve Envision’s economic interest and gives Envision rights to board representation, signaling a move toward tighter group integration, capital restructuring and enhanced institutional influence in the company’s governance.

Envision India Fund to Acquire Mitsubishi’s 4.68% Stake in Sastasundar Healthbuddy

Sastasundar Healthbuddy Limited, a material subsidiary of Health X Platform Limited, has entered into a share purchase agreement with Mitsubishi Corporation and Envision India Fund for a secondary share transaction. The deal involves the sale of 10,13,766 equity shares, representing 4.68% of Sastasundar Healthbuddy’s paid-up capital, at Rs. 493.21 per share, valuing the transaction at nearly Rs. 50 crore.

Under the agreement, Envision India Fund will acquire Mitsubishi Corporation’s entire stake in Sastasundar Healthbuddy, following the satisfaction of agreed terms and conditions. Once completed, Mitsubishi Corporation will fully exit as a shareholder, potentially reshaping the subsidiary’s ownership structure and bringing in a new financial investor without diluting existing share capital at the company level.

Sastasundar Ventures Rebrands as Health X Platform Limited After Regulatory Nod

Health X Platform Limited, previously Sastasundar Ventures Limited, has received formal approval from the Registrar of Companies and the Ministry of Corporate Affairs to change its corporate name. The company remains a publicly listed entity in India, maintaining its existing corporate identification number and legal status as a company limited by shares.

The name change to Health X Platform Limited is effective from 20 February 2026 and applies across its listings on BSE and NSE. According to the incorporation certificate, the change does not affect the rights or liabilities of stakeholders, though the company must display its former name alongside the new one for two years, ensuring continuity and clarity for investors and business partners.

Sastasundar Ventures Sets 9 February Earnings Call for Q3 and Nine-Month FY26 Results

Sastasundar Ventures Limited has scheduled an earnings conference call with analysts and investors on Monday, 9 February 2026 at 4:00 p.m. IST to discuss its financial performance and business updates for the third quarter and nine-month period ended 31 December 2025. The call, to be attended by Founder & Executive Chairman B.L. Mittal and Chief Financial Officer Lokesh Agarwal, underscores the company’s ongoing investor-relations efforts and compliance with SEBI disclosure norms, providing stakeholders with an opportunity to gain deeper insight into the company’s recent results and strategic outlook.